ARS Pharmaceuticals Quote - SPRY

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

12.57

Bid

12.06

Offer

18.00

Volume

1,679,780

12.19 Day's Range 12.9899

5.8054 52 Week Range 18.51

Market Cap

1.222B

Previous Close

12.18

Open

12.26

Last Trade

12.57

Last Trade Time

Financial Volume

US$ 21,143,251

VWAP

12.5869

Average Volume (3m)

1,259,977

Shares Outstanding

97,185,475

Dividend Yield

PE Ratio

-22.45

Earnings Per Share (EPS)

-0.56

Revenue

30k

Net Profit

-54.37M

ARS Pharmaceuticals Inc is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The company is developing neffy, an intranasal epinephrine product in clinical development for pa... ARS Pharmaceuticals Inc is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The company is developing neffy, an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications, and insect bites that could lead to life-threatening anaphylaxis. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

ars-pharma.com

Headquarters

Wilmington, Delaware, USA

Founded

ARS Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SPRY. The last closing price for ARS Pharmaceuticals was US$12.18. Over the last year, ARS Pharmaceuticals shares have traded in a share price range of US$ 5.8054 to US$ 18.51.

ARS Pharmaceuticals currently has 97,185,475 shares in issue. The market capitalisation of ARS Pharmaceuticals is US$1.18 billion. ARS Pharmaceuticals has a price to earnings ratio (PE ratio) of -22.45.

Form 8-K - Current report

ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)

Preliminary fourth quarter neffy® net product revenue of approximately $6.5 million Preliminary cash, cash equivalents and short-term investments of $314.0 million at year-end 2024 to support an...

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

Canada and United Kingdom represent two of the largest markets within the ALK portfolio with plans to expand filings of neffy (epinephrine nasal spray) 2 mg in other key global regions SAN DIEGO...

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions SAN DIEGO, Dec. 19...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	1.4	12.533572068	11.17	12.57	10.7	1562584	11.62974077	CS
4	1.39	12.4329159213	11.18	12.57	10.2	1482277	11.21157831	CS
12	-2.91	-18.7984496124	15.48	18.51	10.2	1259977	13.12585229	CS
26	1.49	13.4476534296	11.08	18.51	8.9055	1166062	13.18434491	CS
52	6.65	112.331081081	5.92	18.51	5.8054	881569	11.75150912	CS
156	7.29	138.068181818	5.28	18.51	2.55	846617	8.79858066	CS
260	7.29	138.068181818	5.28	18.51	2.55	846617	8.79858066	CS

SPRY - Frequently Asked Questions (FAQ)

What is the current ARS Pharmaceuticals share price?

The current share price of ARS Pharmaceuticals is US$ 12.57

How many ARS Pharmaceuticals shares are in issue?

ARS Pharmaceuticals has 97,185,475 shares in issue

What is the market cap of ARS Pharmaceuticals?

The market capitalisation of ARS Pharmaceuticals is USD 1.18B

What is the 1 year trading range for ARS Pharmaceuticals share price?

ARS Pharmaceuticals has traded in the range of US$ 5.8054 to US$ 18.51 during the past year

What is the PE ratio of ARS Pharmaceuticals?

The price to earnings ratio of ARS Pharmaceuticals is -22.45

What is the cash to sales ratio of ARS Pharmaceuticals?

The cash to sales ratio of ARS Pharmaceuticals is 41.87k

What is the reporting currency for ARS Pharmaceuticals?

ARS Pharmaceuticals reports financial results in USD

What is the latest annual turnover for ARS Pharmaceuticals?

The latest annual turnover of ARS Pharmaceuticals is USD 30k

What is the latest annual profit for ARS Pharmaceuticals?

The latest annual profit of ARS Pharmaceuticals is USD -54.37M

What is the registered address of ARS Pharmaceuticals?

The registered address for ARS Pharmaceuticals is 108 W. 13TH STREET, SUITE 100, WILMINGTON, DELAWARE, 19801

What is the ARS Pharmaceuticals website address?

The website address for ARS Pharmaceuticals is ars-pharma.com

Which industry sector does ARS Pharmaceuticals operate in?

ARS Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BTCTBTC Digital Ltd	US$ 8.2697 (73.73%)	61.45M
BDMDBaird Medical Investment Holdings Ltd	US$ 8.80 (62.36%)	18.63M
CRKNCrown Electrokinetics Corporation	US$ 0.1235 (54.96%)	764.86M
NUKKNukkleus Inc	US$ 29.97 (45.98%)	19.09M
GSITGSI Technology	US$ 3.97 (44.36%)	87.7M
DOGZDogness International Corporation	US$ 18.23 (-58.77%)	740.45k
ORKTOrangeKloud Technology Inc	US$ 3.02 (-24.88%)	21.08M
PMAXPowell Max Ltd	US$ 0.6364 (-23.31%)	4.17M
LGCBLinkage Global Inc	US$ 0.2876 (-22.27%)	890.66k
YYAIConnexa Sports Technologies Inc	US$ 0.8299 (-20.20%)	602.48k
CRKNCrown Electrokinetics Corporation	US$ 0.1235 (54.96%)	764.86M
GCTKGlucoTrack Inc	US$ 0.0852 (15.45%)	465.22M
RIMEAlgorhythm Holdings Inc	US$ 0.0406 (-4.02%)	387.23M
TGLTreasure Global Inc	US$ 0.2459 (14.75%)	267.1M
NVDANVIDIA Corporation	US$ 137.71 (3.10%)	201.4M